A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 186
- 试验地点
- 2
- 主要终点
- PFS
研究概览
简要总结
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Diagnosed as advanced non-small cell lung cancer
- •2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation
排除标准
- •The patient is diagnosed with small cell lung cancer
研究组 & 干预措施
KRAS mutation
patients carry with KRAS mutation
干预措施: immunity therapy (Drug)
ALK fusion
patients carry with ALK fusion
干预措施: immunity therapy (Drug)
ERBB2 mutation
patients carry with ERBB2 mutation
干预措施: immunity therapy (Drug)
MET skipping/amplication
patients carry with MET skipping/amplication
干预措施: immunity therapy (Drug)
RET fusion
patients carry with RET fusion
干预措施: immunity therapy (Drug)
BRAF mutation
patients carry with BRAF mutation
干预措施: immunity therapy (Drug)
结局指标
主要结局
PFS
时间窗: January 2021- January 2021 (1 year)
Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)
次要结局
未报告次要终点
研究者
Yongchang Zhang
Director, Head of Medical Oncology, Principal Investigator, Clinical Professor
Hunan Province Tumor Hospital